S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Why Turkey's currency is crashing after Erdogan got reelected
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
The single greatest medical breakthrough of all time? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Why Turkey's currency is crashing after Erdogan got reelected
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
The single greatest medical breakthrough of all time? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Why Turkey's currency is crashing after Erdogan got reelected
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
The single greatest medical breakthrough of all time? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Why Turkey's currency is crashing after Erdogan got reelected
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
The single greatest medical breakthrough of all time? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
TSE:GUD

Knight Therapeutics (GUD) Stock Forecast, Price & News

C$4.98
+0.03 (+0.61%)
(As of 06/9/2023 ET)
Compare
Today's Range
C$4.95
C$4.98
50-Day Range
C$4.42
C$4.98
52-Week Range
C$4.28
C$6.20
Volume
84,921 shs
Average Volume
123,292 shs
Market Capitalization
C$542.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$5.97

GUD stock logo

About Knight Therapeutics (TSE:GUD) Stock

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Receive GUD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GUD Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Closing Bell: Knight Therapeutics Inc up on Monday (GUD)
Knight Therapeutics (TSE:GUD) Price Target Cut to C$6.50
Knight Therapeutics (TSE:GUD) Hits New 52-Week Low at $4.92
Knight Therapeutics Inc
See More Headlines

GUD Price History

GUD Company Calendar

Last Earnings
3/23/2023
Today
6/10/2023
Next Earnings (Estimated)
8/10/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
698
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$5.97
High Stock Price Forecast
C$6.50
Low Stock Price Forecast
C$5.40
Forecasted Upside/Downside
+19.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

P/E Growth
-1013.5
Net Income
C$-15,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$312.35 million
Cash Flow
C$1.29 per share
Book Value
C$7.44 per share

Miscellaneous

Free Float
N/A
Market Cap
C$542.02 million
Optionable
Not Optionable
Beta
0.52

Key Executives

  • Mr. Jonathan Ross Goodman B.A. (Age 54)
    BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman
    Comp: $250.94k
  • Ms. Samira Sakhia BCom (Age 55)
    CA, CPA, MBA, Pres, CEO & Director
    Comp: $674.28k
  • Mr. Arvind Utchanah
    Chief Financial Officer
  • Ms. Amal Khouri B.Sc.
    M.B.A., Chief Bus. Officer
  • Mr. Jeff Martens
    Global VP of Commercial
  • Mr. Stephani Saverio
    VP of Bus. Devel.
  • Mr. Leopoldo Bosano
    Vice-Pres of Manufacturing & Operations
  • Ms. Monica Percario
    Global VP of Scientific Affairs
  • Ms. Susan Caroline Emblem
    Global VP of HR













GUD Stock - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GUD shares.
View GUD analyst ratings
or view top-rated stocks.

What is Knight Therapeutics' stock price forecast for 2023?

2 Wall Street analysts have issued 12 month price objectives for Knight Therapeutics' stock. Their GUD share price forecasts range from C$5.40 to C$6.50. On average, they expect the company's share price to reach C$5.97 in the next year. This suggests a possible upside of 19.8% from the stock's current price.
View analysts price targets for GUD
or view top-rated stocks among Wall Street analysts.

How have GUD shares performed in 2023?

Knight Therapeutics' stock was trading at C$5.18 on January 1st, 2023. Since then, GUD shares have decreased by 3.9% and is now trading at C$4.98.
View the best growth stocks for 2023 here
.

When is Knight Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GUD earnings forecast
.

How were Knight Therapeutics' earnings last quarter?

Knight Therapeutics Inc. (TSE:GUD) released its quarterly earnings results on Thursday, March, 23rd. The company reported $0.02 EPS for the quarter. The company earned $81.66 million during the quarter, compared to analysts' expectations of $62 million. Knight Therapeutics had a negative net margin of 4.81% and a negative trailing twelve-month return on equity of 1.82%.

What other stocks do shareholders of Knight Therapeutics own?
What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."

How do I buy shares of Knight Therapeutics?

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of GUD stock can currently be purchased for approximately C$4.98.

How much money does Knight Therapeutics make?

Knight Therapeutics (TSE:GUD) has a market capitalization of C$542.02 million and generates C$312.35 million in revenue each year. The company earns C$-15,020,000.00 in net income (profit) each year or C($0.14) on an earnings per share basis.

How many employees does Knight Therapeutics have?

The company employs 698 workers across the globe.

How can I contact Knight Therapeutics?

Knight Therapeutics' mailing address is 3400 de Maisonneuve Boulevard West, Suite 1055, Montreal, QC H3Z 3B8, Canada. The official website for the company is www.gud-knight.com. The company can be reached via phone at 514-484-4483.

This page (TSE:GUD) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -